High throughput physiological screening of iPSC-derived cardiomyocytes for drug development

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Stem Cell Biology

Background:

• Current cardiac drug discovery relies on animal and cellular models lacking human physiological relevance and throughput.
• Inadequate models lead to high failure rates in drug development and post-market issues due to unforeseen cardiotoxicity.
• There is a critical need for human-relevant models to improve the efficiency and success of cardiovascular drug development.

Purpose of the Study:

• To review emerging technologies for high-throughput measurement of cardiomyocyte physiology.
• To discuss the potential and challenges of using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) in drug discovery.
• To highlight the integration of human context into early-stage drug development for cardiovascular diseases.

Main Methods:

• Review of current literature on high-throughput screening technologies for cardiomyocyte function.
• Analysis of iPSC-CM applications in modeling cardiac diseases and drug-induced cardiotoxicity.
• Discussion of the advantages and limitations of iPSC-CMs compared to traditional models.

Main Results:

• Emerging technologies enable high-throughput physiological measurements in cardiomyocytes.
• iPSC-CMs provide a human-relevant platform for disease modeling and drug testing.
• Significant progress has been made in utilizing iPSC-CMs for predicting drug efficacy and safety.

Conclusions:

• iPSC-CMs represent a promising advancement for improving cardiac drug discovery by providing human physiological context and higher throughput.
• Addressing current challenges in iPSC-CM technology and standardization is crucial for widespread adoption.
• The use of iPSC-CMs has the potential to significantly reduce drug development costs and failure rates.